多瑞吉治疗中晚期癌症疼痛的临床疗效与生活质量分析  

The Analysis of Clinic Effects and Quality of Life in the Treatment for Moderate to Sever Cancer Pain

作　　者：邹冰心[1] 黄作平[1] 谢强[1] 赵荡[1] 王立根[1] 

机构地区：[1]武警广东总队医院内三科,广州510507

出　　处：《肿瘤防治研究》2007年第3期207-208,共2页Cancer Research on Prevention and Treatment

摘　　要：目的探讨多瑞吉与美施康定治疗中、重度癌症疼痛的疗效与生活质量。方法将126例中、重度癌症疼痛的患者随机分两组,分别接受多瑞吉(A组)与美施康定(B组)治疗,并记录其疗效、副作用及生存质量。结果多瑞吉与美施康定的疼痛缓解率分别为88.89%、87.30%,疼痛缓解率与生活质量差异均无统计学意义(P>0.05)。多瑞吉组中的恶心、便秘的副作用发生率则低于美施康定(P<0.01)。结论多瑞吉是治疗中、重度癌症疼痛的安全、可靠、副作用小的药物。Objective To investigate the efficacy,side effects and quality of life between transdermal fentanyl plaster （Durogesic） and sustained release morphine tablet （MS-Contin） in the treatment for moderate to sever cancer pain. Methods 126 patients were randomized into Durogesic group （group A） and MS- Contin group （group B）. The two groups received Durogesic and MS-contin respectively. Then the efficacy, side effects and quality of life were recorded. Results The difference of the effective rates and quality of life of Durogesic and MS-Contin were not significant. However, the incidence of vomit and constipation were significantly higher in the MS-Contin group than that of in the Durogesic group. Conclusion The Durogesic is a drug that is safe, reliable and has little side effect in treating moderate to sever cancer pain.

关 键 词：多瑞吉 美施康定 癌症疼痛 

分 类 号：R730.6[医药卫生—肿瘤]